Medicenna Therapeutics (TSE:MDNA) Announces Quarterly Earnings Results

Medicenna Therapeutics (TSE:MDNA – Get Free Report) released its quarterly earnings results on Monday. The company reported C($0.04) EPS for the quarter, FiscalAI reports. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 360.29%.

Medicenna Therapeutics Price Performance

MDNA opened at C$0.36 on Tuesday. The company has a debt-to-equity ratio of 6.22, a current ratio of 1.25 and a quick ratio of 4.65. The company has a market capitalization of C$33.69 million, a price-to-earnings ratio of -1.66 and a beta of 2.49. The firm’s fifty day moving average price is C$0.42 and its two-hundred day moving average price is C$0.53. Medicenna Therapeutics has a 1 year low of C$0.34 and a 1 year high of C$1.78.

About Medicenna Therapeutics

(Get Free Report)

Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.

Read More

Earnings History for Medicenna Therapeutics (TSE:MDNA)

Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.